SCHEMBL14714718

SCHEMBL14714718

CCCCCCCC/C=C\CCCCCCC1(C(=O)O)CC1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 3/20 0.49
PTPN1 P18031 3/20 0.49
PPARG P37231 3/20 0.49
PPARD Q03181 3/20 0.49
PPARA Q07869 3/20 0.49
TOP1 P11387 3/20 0.49
MAPT P10636 2/20 0.49
BLM P54132 2/20 0.49
HSD17B10 Q99714 2/20 0.49
FABP4 P15090 2/20 0.49
DUSP3 P51452 2/20 0.49
PTPN7 P35236 2/20 0.49
GMNN O75496 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX15 P16050 1/20 0.49
APEX1 P27695 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2053235 0.88 AKR1B1 (0.37) PTPN1PPARGPPARDPPARAHSD17B10
SCHEMBL11159042 0.76 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL11162359 0.76 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL11159043 0.76 TERT (0.50) TERTPTPN1PPARGPPARDPPARA
SCHEMBL3447981 0.76 TERT (0.53) TERTPTPN1PPARGPPARDPPARA
SCHEMBL8456883 0.75 TERT (0.45) TERTPTPN1PPARGPPARDPPARA
SCHEMBL8456891 0.75 TERT (0.45) TERTPTPN1PPARGPPARDPPARA
SCHEMBL9518086 0.73 CES2 (0.38)
Bicarbonate SCHEMBL10592426 0.73 TERT (0.75) TERTPTPN1PPARGPPARDPPARA
Bicarbonate SCHEMBL3789802 0.73 TERT (0.75) TERTPTPN1PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2687205-B1 FENTANYL TRANSDERMAL PATCH ICURE PHARMACEUTICAL CORP (KR) 2020-12-23 EP claimed
US-20190091168-A1 FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) 2019-03-28 US claimed
US-9295655-B2 Fentanyl transdermal patch ICURE (KR) 2016-03-29 US claimed
EP-2687205-A2 FENTANYL TRANSDERMAL PATCH Icure Pharmaceutical Corp. (KR) 2014-01-22 EP claimed
US-20140005617-A1 FENTANYL TRANSDERMAL PATCH ICURE (KR) 2014-01-02 US claimed
US-20130165875-A1 TRANSDERMAL ABSORPTION PREPARATION ICURE PHARMACEUTICAL INC. (KR) 2013-06-27 US claimed
EP-2561865-A2 TRANSDERMAL ABSORPTION PREPARATION Icure Pharmaceutical Inc. (KR) 2013-02-27 EP claimed
CN-102946873-A Percutaneous absorption preparation ICURE PHARM INC 2013-02-27 CN claimed
CN-113166024-A Aromatic compounds and their medical use 巴斯夫股份公司 2021-07-23 CN disclosed
EP-2687205-B1 FENTANYL TRANSDERMAL PATCH ICURE PHARMACEUTICAL CORP (KR) 2020-12-23 EP disclosed
US-20190091168-A1 FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) 2019-03-28 US disclosed
US-9295655-B2 Fentanyl transdermal patch ICURE (KR) 2016-03-29 US disclosed
CN-102946873-B percutaneous absorption preparation ICURE PHARM INC 2015-05-13 CN disclosed
EP-2687205-A2 FENTANYL TRANSDERMAL PATCH Icure Pharmaceutical Corp. (KR) 2014-01-22 EP disclosed
US-20140005617-A1 FENTANYL TRANSDERMAL PATCH ICURE (KR) 2014-01-02 US disclosed
US-20130165875-A1 TRANSDERMAL ABSORPTION PREPARATION ICURE PHARMACEUTICAL INC. (KR) 2013-06-27 US disclosed
EP-2561865-A2 TRANSDERMAL ABSORPTION PREPARATION Icure Pharmaceutical Inc. (KR) 2013-02-27 EP disclosed
CN-102946873-A Percutaneous absorption preparation ICURE PHARM INC 2013-02-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190091168-A1 FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG APP, PSEN2, PSEN1 TERT 912/4885PTPN1 4072/4885PPARG 128/4885
US-20140005617-A1 FENTANYL TRANSDERMAL PATCH CD69, OPRD1, OPRL1 TERT 2255/4885PTPN1 4839/4885PPARG 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.